Calypte Biomedical Issues Update on Informal SEC Inquiry
July 19 2004 - 9:30AM
PR Newswire (US)
Calypte Biomedical Issues Update on Informal SEC Inquiry
PLEASANTON, Calif., July 19 /PRNewswire-FirstCall/ -- Calypte
Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) announced
today that the SEC Division of Enforcement notified the Company
that the informal inquiry that its staff was conducting has been
terminated and that no enforcement action has been recommended by
the Commission at this time. About Calypte Biomedical: Calypte
Biomedical Corporation, headquartered in Pleasanton, California, is
a public healthcare company dedicated to the development and
commercialization of in vitro diagnostic tests, primarily for the
detection of antibodies to Human Immunodeficiency Virus (HIV), and
other sexually transmitted and infectious diseases. Calypte's
currently marketed laboratory- based tests include an enzyme
immunoassay (EIA) HIV-1 antibody screening test and an HIV-1
antibody western blot supplemental test, the only two FDA- approved
HIV-1 antibody tests for use on urine samples, as well as an FDA-
approved serum HIV-1 antibody western blot supplemental test.
Calypte is actively engaged in developing new test products for the
rapid detection of HIV and other infectious diseases. Calypte
believes that there is a significant need for rapid detection of
such diseases globally to control their proliferation, particularly
in lesser-developed countries, which lack the medical
infrastructure to support laboratory-based testing. Calypte
believes that testing for HIV and other infectious diseases may
make important contributions to public health. Company Contact:
Investor Relations Contact: Richard Brounstein, CFO Tim Clemensen
(925) 730-7200 Rubenstein Investor Relations email: Phone:
212-843-9337 Email: DATASOURCE: Calypte Biomedical Corporation
CONTACT: Richard Brounstein, CFO of Calypte Biomedical Corporation,
+1-925-730-7200, or ; or Tim Clemensen of Rubenstein Investor
Relations, +1-212-843-9337, or , for Calypte Biomedical Corporation
Web site: http://www.calypte.com/
Copyright